The first vaccine against malaria to undergo wide-scale testing shows that youngsters who got it were about half as likely to come down with the disease over a 14-month follow-up period as were those who didn't receive the vaccine.
An international group of scientists report the findings online October 18 in the New England Journal of Medicine. The researchers unveiled data on 6,000 African children, ages 5 months to 17 months, who were randomly assigned to get either a three-dose malaria vaccine or a control vaccine — in this case, for rabies.
Note: To comment, Science News subscribing members must now establish a separate login relationship with Disqus. Click the Disqus icon below, enter your e-mail and click “forgot password” to reset your password. You may also log into Disqus using Facebook, Twitter or Google.